Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Immunitas Therapeutics on the deal. Immunitas Therapeutics, an immuno-oncology biotech company, announced its $58 million Series B financing round. The round...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here